-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
ATyr Pharma, Inc. (NASDAQ:LIFE) Short Interest Up 5.4% in August
ATyr Pharma, Inc. (NASDAQ:LIFE) Short Interest Up 5.4% in August
aTyr Pharma, Inc. (NASDAQ:LIFE – Get Rating) saw a significant growth in short interest in the month of August. As of August 31st, there was short interest totalling 341,600 shares, a growth of 5.4% from the August 15th total of 324,000 shares. Based on an average trading volume of 131,700 shares, the days-to-cover ratio is presently 2.6 days.
aTyr Pharma Stock Down 3.9 %
LIFE stock opened at $2.93 on Wednesday. The firm's fifty day moving average is $3.49 and its 200 day moving average is $3.76. aTyr Pharma has a 52 week low of $2.60 and a 52 week high of $13.10.
Get aTyr Pharma alerts:aTyr Pharma (NASDAQ:LIFE – Get Rating) last announced its quarterly earnings data on Monday, August 15th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.01). During the same quarter in the previous year, the company earned ($0.64) earnings per share. On average, research analysts forecast that aTyr Pharma will post -1.81 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on the stock. StockNews.com downgraded shares of aTyr Pharma from a "hold" rating to a "sell" rating in a research note on Wednesday, September 14th. HC Wainwright raised their price target on aTyr Pharma from $11.00 to $35.00 and gave the company a "buy" rating in a research report on Thursday, July 21st. Finally, Piper Sandler increased their price objective on aTyr Pharma from $11.00 to $14.00 and gave the company an "overweight" rating in a research report on Monday, August 15th.Insider Activity
In other news, CEO Sanjay Shukla bought 15,000 shares of the firm's stock in a transaction that occurred on Friday, July 1st. The shares were acquired at an average price of $2.88 per share, with a total value of $43,200.00. Following the acquisition, the chief executive officer now owns 40,798 shares of the company's stock, valued at approximately $117,498.24. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.36% of the stock is owned by company insiders.
Hedge Funds Weigh In On aTyr Pharma
Large investors have recently bought and sold shares of the stock. Raymond James & Associates bought a new position in shares of aTyr Pharma in the fourth quarter worth approximately $184,000. Dimensional Fund Advisors LP raised its stake in shares of aTyr Pharma by 1.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 226,712 shares of the biotechnology company's stock valued at $1,694,000 after acquiring an additional 2,433 shares during the last quarter. Qube Research & Technologies Ltd purchased a new stake in shares of aTyr Pharma during the fourth quarter worth about $87,000. Tikvah Management LLC bought a new stake in shares of aTyr Pharma in the fourth quarter worth about $9,157,000. Finally, GSA Capital Partners LLP purchased a new stake in aTyr Pharma in the 4th quarter worth approximately $439,000. 65.58% of the stock is owned by hedge funds and other institutional investors.
aTyr Pharma Company Profile
(Get Rating)
aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.
Recommended Stories
- Get a free copy of the StockNews.com research report on aTyr Pharma (LIFE)
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
- Is Ford Rolling To A Rebound After Its Q3 Warning
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
aTyr Pharma, Inc. (NASDAQ:LIFE – Get Rating) saw a significant growth in short interest in the month of August. As of August 31st, there was short interest totalling 341,600 shares, a growth of 5.4% from the August 15th total of 324,000 shares. Based on an average trading volume of 131,700 shares, the days-to-cover ratio is presently 2.6 days.
ATyr醫藥公司(納斯達克:LIFE-GET評級)看到空頭股數在8月份有顯著增長。截至8月31日,空頭股數共有34.16萬股,較8月15日的32.4萬股增長5.4%。基於131,700股的平均成交量,目前的天數與回補比率為2.6天。
aTyr Pharma Stock Down 3.9 %
ATyr Pharma股價下跌3.9%
LIFE stock opened at $2.93 on Wednesday. The firm's fifty day moving average is $3.49 and its 200 day moving average is $3.76. aTyr Pharma has a 52 week low of $2.60 and a 52 week high of $13.10.
人壽股票週三開盤報2.93美元。該公司的50日移動均線切入位為3.49美元,200日移動均線切入位為3.76美元。ATyr Pharma的52周低點為2.60美元,52周高點為13.10美元。
aTyr Pharma (NASDAQ:LIFE – Get Rating) last announced its quarterly earnings data on Monday, August 15th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.01). During the same quarter in the previous year, the company earned ($0.64) earnings per share. On average, research analysts forecast that aTyr Pharma will post -1.81 earnings per share for the current fiscal year.
ATyr醫藥(納斯達克:LIFE-GET評級)最近一次公佈季度收益數據是在8月15日(星期一)。這家生物技術公司公佈的季度每股收益(EPS)為0.44美元,低於分析師普遍預期的0.43美元和0.01美元。去年同期,該公司每股收益為0.64美元。研究分析師平均預測,aTyr Pharma本財年每股收益將達到1.81美元。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
Insider Activity
內幕活動
In other news, CEO Sanjay Shukla bought 15,000 shares of the firm's stock in a transaction that occurred on Friday, July 1st. The shares were acquired at an average price of $2.88 per share, with a total value of $43,200.00. Following the acquisition, the chief executive officer now owns 40,798 shares of the company's stock, valued at approximately $117,498.24. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.36% of the stock is owned by company insiders.
在其他新聞方面,首席執行官桑賈伊·舒克拉在7月1日星期五的一筆交易中購買了15,000股該公司的股票。這些股票是以每股2.88美元的平均價格收購的,總價值為43,200.00美元。收購完成後,這位首席執行官現在擁有40,798股公司股票,價值約117,498.24美元。此次收購是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可在此超鏈接。4.36%的股份由公司內部人士持有。
Hedge Funds Weigh In On aTyr Pharma
對衝基金參與aTyr Pharma
Large investors have recently bought and sold shares of the stock. Raymond James & Associates bought a new position in shares of aTyr Pharma in the fourth quarter worth approximately $184,000. Dimensional Fund Advisors LP raised its stake in shares of aTyr Pharma by 1.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 226,712 shares of the biotechnology company's stock valued at $1,694,000 after acquiring an additional 2,433 shares during the last quarter. Qube Research & Technologies Ltd purchased a new stake in shares of aTyr Pharma during the fourth quarter worth about $87,000. Tikvah Management LLC bought a new stake in shares of aTyr Pharma in the fourth quarter worth about $9,157,000. Finally, GSA Capital Partners LLP purchased a new stake in aTyr Pharma in the 4th quarter worth approximately $439,000. 65.58% of the stock is owned by hedge funds and other institutional investors.
大型投資者最近買賣了該股的股票。Raymond James&Associates在第四季度購買了價值約18.4萬美元的aTyr Pharma股票的新頭寸。Dimension Fund Advisors LP在第四季度將其在aTyr Pharma的股份增加了1.1%。Dimension Fund Advisors LP現在擁有226,712股這家生物技術公司的股票,價值1,694,000美元,此前在上個季度又購買了2,433股。Qube Research&Technologies Ltd在第四季度購買了aTyr Pharma價值約8.7萬美元的新股。Tikvah Management LLC在第四季度購買了aTyr Pharma價值約9,157,000美元的新股。最後,GSA Capital Partners LLP在第四季度購買了aTyr Pharma的新股份,價值約43.9萬美元。65.58%的股票由對衝基金和其他機構投資者持有。
aTyr Pharma Company Profile
ATyr製藥公司簡介
(Get Rating)
(獲取評級)
aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.
ATyr Pharma,Inc.是一家生物療法公司,在美國從事基於新免疫途徑的藥物的發現和開發。該公司的主要候選藥物是efzofitimod,這是一種NRP2的選擇性調節劑,正在進行肺結節病的第二階段臨牀試驗;以及1b/2a階段的臨牀試驗,用於治療其他間質性肺部疾病,如慢性過敏性肺炎和與ILD相關的結締組織疾病。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on aTyr Pharma (LIFE)
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
- Is Ford Rolling To A Rebound After Its Q3 Warning
- 免費獲取StockNews.com關於aTyr Pharma(LIFE)的研究報告
- 連續60年提高股息的3只防御性股票
- 3家航空公司股票陷入持有格局
- Roku股票下跌,但並未出局
- 如果你渴望價值,那就嚐嚐露絲的好客之道吧
- 福特在第三季度發出警告後是否正在反彈
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受aTyr Pharma Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對aTyr Pharma和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧